Study Design: This was a prospective cohort study of 44 adults with a primary diagnosis of major depressive disorder.* The study compared 8 weeks of treatment guided by GeneSight® to unguided treatment as usual (TAU).
Faster time to improvement: Physician medication changes guided by GeneSight pharmacogenomic testing improved time to depression symptom relief compared to current standard of care.
Genetically optimal medications prescribed more often: When clinicians used GeneSight to guide treatment, subjects were more often prescribed medications identified as genetically optimal for that subject.
Improved clinical outcomes: This study showed a 4-fold greater improvement in subjects’ depressive symptoms at week 8 (QIDS-C16) when treatment was informed by GeneSight compared to treatment as usual (TAU).
*Minimum Score of 14 on the 17-item Hamilton Rating Scale for Depression (HAM-D17).